Role of Adjuvant Chemotherapy in NSCLC (Stages I to III)
Role of Adjuvant Chemotherapy in NSCLC (Stages I to III)
复制标题
DOI：
10.1016/j.soc.2011.07.011
复制
发表时间：
2011-10-01
影响因子：
1.9
通讯作者：
Bueno, Raphael
中科院分区：
文献类型：
--
作者：
Coleman, Melissa H.;Bueno, Raphael
手术切除是早期非小细胞肺癌的主要治疗手段。IA期的存活率最多保持在80%，需要开发有效的全身治疗。几项大型随机对照试验和荟萃分析为I至III期患者使用辅助化疗提供了证据，并且是护理标准的基础。以顺铂为基础的辅助化疗方案在5年时显示出4%至15%的生存优势。鉴于这种适度的生存益处，研究集中在识别预后和预测标志物，以帮助选择适当的辅助化疗方案。
Complete surgical resection is the main therapy for early-stage non-small cell lung cancer. Survival rates remain, at best, 80% for stage IA, necessitating the development of effective systemic therapy. Several large randomized control trials and meta-analyses provide evidence for the use of adjuvant chemotherapy for stage I to III, and are the basis for the standards of care. Cisplatin-based adjuvant chemotherapy regimens have shown 4% to 15% survival advantage at 5 years. Given this modest survival benefit, research is focused on the identification of prognostic and predictive markers to aid in the selection of appropriate adjuvant chemotherapy regimens.